Tumor Boards and Prescribing Comfort With Durvalumab Plus BCG

In this final installment, Mark D. Tyson II, MD, MPH, raises tumor boards as a coordination tool the conversation hadn't yet touched on, noting they exist in both community and academic settings and offer a structured venue for urologists and medical oncologists to align on complex cases.

Drakaki then asks Tyson, given the recent approval of durvalumab (Imfinzi) plus BCG following the POTOMAC trial (NCT03528694), what his comfort level is for offering the combination to patients. Tyson says he currently reserves it largely for patients who could reasonably be considered for cystectomy but would prefer to avoid it, describing a typical candidate as BCG-naive with high-volume T1 disease. Drakaki agrees with his framing, noting that medical oncology is typically the second stop after that initial decision is made, and shares that she had evaluated a similar patient, a young woman, just the day before who fit that exact profile.

The program closes with Tyson thanking Drakaki for the conversation and expressing interest in continued collaboration, followed by his thanks to the viewing audience for joining this special report on how academic centers coordinate high-risk NMIBC care.